PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: CPG 7909
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00043407
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00043420
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
Phase 2
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2002-07-16
- Last Posted Date
- 2008-10-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT00041704
- Locations
- πΊπΈ
Versicor, Inc., King of Prussia, Pennsylvania, United States
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00040014
- Locations
- π¬π§
Pfizer Investigational Site, Leicester, United Kingdom
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- Non-Hodgkin LymphomaHodgkin DiseaseThrombocytopenia
- First Posted Date
- 2002-06-17
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00039910
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4740
- Registration Number
- NCT00038467
- Locations
- π¬π§
Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- Sarcoma
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00038311
- Locations
- πΊπΈ
Pfizer Investigational Site, Houston, Texas, United States
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2010-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00038103
- Locations
- π΅π
Pfizer Investigational Site, Manila, Philippines
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Phase 1
Completed
- Conditions
- Unspecified Adult Solid TumorChemotherapyLiver DysfunctionNeoplasms, Solid Tumor
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00037804
- Locations
- πΊπΈ
Research Center, Marshfield, Wisconsin, United States
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- NeoplasmsThrombocytopeniaMultiple MyelomaLymphoma, Malignant
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00037791
- Locations
- π²π½
Pfizer Investigational Site, Mexico City, DF, Mexico
Β© Copyright 2025. All Rights Reserved by MedPath